⚠ Evidence warning: Clinical trials or other evidence do not support the claims that the fatigue benefit of ginseng is cumulative with continued dosing, that the trial is the basis for a National Comprehensive Cancer Network guideline mention, that oncology nutrition consultants commonly suggest American ginseng for post-treatment fatigue, and that ginseng gives trained athletes modest, real performance benefits. This page keeps it as a report of what people, websites or other media say.
Ginseng for Energy and Fatigue
Ginseng has been used as an energizing and "restorative" tonic for at least 2,000 years across China, Korea, and Japan, and modern clinical trials have largely confirmed the traditional claim — with some surprising specificity. The single best-supported indication is cancer-related fatigue: the Barton 2013 Wisconsin trial of American ginseng (Panax quinquefolius) at 2,000 mg/day improved the general-fatigue score of the MFSI-SF (Multidimensional Fatigue Symptom Inventory–Short Form) by 20 points versus 10.3 points on placebo at eight weeks, after a trend at week four (the trial's planned main test) that did not reach statistical significance. A second well-supported indication is idiopathic chronic fatigue, where a 2013 randomized trial of 1-2 g/day of a Panax ginseng extract improved mental-fatigue scores, although total fatigue scores did not differ significantly from placebo. The traditional distinction between "warming" Korean ginseng and "cooling" American ginseng turns out to map onto the modern molecular finding that Korean ginseng is higher in the stimulant-like Rg1 ginsenoside while American ginseng is higher in the calmer Rb1 ginsenoside — which is why practitioners traditionally match American ginseng to fatigue with anxiety, and Korean red ginseng to flat, low-libido fatigue.
Table of Contents
- Two Thousand Years of Use as a Tonic
- Korean "Warming" vs American "Cooling" — the Rg1/Rb1 Molecular Basis
- The Barton 2013 Wisconsin Trial — Cancer-Related Fatigue
- Chronic Fatigue Syndrome and Idiopathic Chronic Fatigue
- Pooled Herbal Trials for Cancer-Related Fatigue
- Mitochondrial Bioenergetics — The Mechanism Beneath the Effect
- Hypothalamic-Pituitary-Adrenal-Axis Cortisol Normalization
- Exercise Performance and Athletic Endurance
- Practical Dosing and Forms
- What Ginseng Does Not Do for Fatigue
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
Two Thousand Years of Use as a Tonic
The Chinese pharmacopoeia Shennong Bencao Jing (compiled approximately 100 CE, attributed to a much older oral tradition) ranks ginseng (ren shen, "person root," named for the human-figure-like shape of mature roots) in the highest "superior" class of medicines — substances thought safe to use long-term to maintain health rather than only to treat acute disease. The two-thousand-year traditional indication list maps remarkably well onto modern findings: deficiency of "qi" (now interpreted as low energy, fatigue, weakness), restoration after debilitating illness, support of the elderly, and support of recovery from major exertion or childbirth.
The Korean medical tradition, while sharing the Chinese theoretical framework, places even greater emphasis on ginseng. Korea is the world's largest producer of cultivated ginseng for medicinal use, and the steamed-and-dried "red ginseng" preparation (hong sam, in Korean) developed in Korea is now the most-studied single ginseng preparation in modern clinical literature.
In modern Western herbalism, the 1947 Russian scientist Nikolai Lazarev coined the term adaptogen to describe a class of substances — ginseng prominent among them — that help an organism non-specifically resist a wide variety of stressors. Lazarev's framework was extended by his colleague Israel Brekhman to formalize three criteria for an adaptogen: (1) non-specific increase in resistance to physical, chemical, or biological stressors, (2) normalizing effect (raising what is too low, lowering what is too high), and (3) innocuous nature (low toxicity, no major disruption of normal physiology). Ginseng was the prototypical adaptogen in Lazarev and Brekhman's research program, and modern clinical evidence has largely vindicated the classification — particularly for fatigue indications.
Korean "Warming" vs American "Cooling" — the Rg1/Rb1 Molecular Basis
One of the more interesting findings in modern ginseng pharmacology is the rough correspondence between traditional Chinese pharmacological classification (warming, cooling, neutral) and measurable ginsenoside content. Panax ginseng (Korean or Asian ginseng) is traditionally classified as warming and stimulating, while Panax quinquefolius (American ginseng, native to Wisconsin, Minnesota, and the Appalachian range) is traditionally classified as cooling and calming — despite being botanically very similar species in the same genus.
HPLC analysis of root material from both species shows a consistent difference in the ratio of two principal ginsenosides:
- Ginsenoside Rg1 — a protopanaxatriol-class ginsenoside with stimulant-like central nervous system (CNS) effects in preclinical models (increased locomotor activity, acetylcholine release, dopaminergic signaling). Korean Panax ginseng typically contains roughly twice as much Rg1 as American ginseng.
- Ginsenoside Rb1 — a protopanaxadiol-class ginsenoside with calmer effects in preclinical models (anxiolytic, neuroprotective, anti-inflammatory). American Panax quinquefolius typically contains substantially higher Rb1 than Korean ginseng.
So the traditional "warming Korean ginseng vs cooling American ginseng" distinction has a fair correspondence to the modern molecular finding that Korean ginseng is richer in the more stimulant-like Rg1 while American ginseng is richer in the more sedative-like Rb1. The traditional matching that practitioners describe for fatigue:
- Flat fatigue, low motivation, low libido, "blah" affect, cold extremities — practitioners traditionally favour Korean red ginseng (Panax ginseng); 1-2 g/day of standardized extract is the amount commonly described.
- Fatigue with anxiety, insomnia, hot flashes, irritability, or "wired and tired" pattern — practitioners traditionally favour American ginseng (Panax quinquefolius); 1-2 g/day is the amount commonly described.
- Cancer-related fatigue specifically — the Mayo and Wisconsin trials used American ginseng (Panax quinquefolius), because cancer patients often have the wired-tired-anxious pattern and tolerate the cooler preparation better.
The Barton 2013 Wisconsin Trial — Cancer-Related Fatigue
The single most influential modern clinical trial of ginseng for fatigue is the Barton 2013 Wisconsin ginseng trial (Mayo Clinic / Alliance for Clinical Trials in Oncology study N07C2). The trial enrolled 364 fatigued cancer survivors from 40 institutions (mostly breast cancer, also colorectal, lung, and others) with at least one month of clinically significant fatigue at baseline; some were still receiving cancer treatment and some had completed it. Participants were randomized to:
- 2,000 mg/day of Wisconsin-grown American ginseng (Panax quinquefolius), 1,000 mg twice daily for 8 weeks
- Identical-appearing placebo
The planned main test (primary endpoint) was the change in the general-fatigue subscale of the MFSI-SF (Multidimensional Fatigue Symptom Inventory–Short Form) at 4 weeks. Key results:
- At 4 weeks (the planned main test), the general-fatigue score improved by 14.4 points with ginseng versus 8.2 with placebo (P = .07) — a trend, not a statistically significant difference
- At 8 weeks, the general-fatigue score improved by 20 points with ginseng versus 10.3 with placebo (P = .003), a statistically significant difference
- The effect was detectable but smaller at 4 weeks, suggesting cumulative benefit with continued dosing
- People still receiving cancer treatment reported greater benefit than those who had completed treatment
- Side effects, by self-report and by the National Cancer Institute's grading criteria, did not differ statistically between the ginseng and placebo arms — no excess insomnia, blood pressure changes, or gastrointestinal complaints
- No interactions with chemotherapy efficacy were detected in the post-hoc analysis
The Barton trial was preceded by a smaller phase 2 dose-finding study (Barton 2010) that compared 750, 1,000, and 2,000 mg/day of American ginseng with placebo in 290 people over 8 weeks. It found only non-significant trends in favour of the 1,000 and 2,000 mg/day doses (for example, the SF-36 vitality score rose 10.5-14.6 points on those doses versus 7.3-7.8 on placebo and 750 mg/day); the authors judged 1,000-2,000 mg/day worth further study, and the phase 3 trial used 2,000 mg/day.
The Mayo/Alliance result is the basis for the NCCN (National Comprehensive Cancer Network) clinical practice guideline mention of ginseng as one of the options for cancer-related fatigue management, alongside exercise (the strongest single intervention), mind-body therapies, and pharmacologic options like methylphenidate. For practical purposes, oncology nutrition consultants now commonly suggest American ginseng 1,000-2,000 mg/day for patients dealing with persistent post-treatment fatigue.
The 2024 fatigue guideline of the American Society of Clinical Oncology (ASCO) and the Society for Integrative Oncology reviewed 113 randomized trials published from 2013 to 2023. It found that exercise, cognitive behavioural therapy and mindfulness-based programs improved cancer-related fatigue both during and after treatment, and that American ginseng (like tai chi and qigong) showed benefit during cancer treatment; it states that “psychoeducation and American ginseng may be recommended in adults undergoing cancer treatment.” For survivors who have completed treatment, the guideline's list (exercise, cognitive behavioural therapy, mindfulness-based programs, yoga, acupressure, moxibustion) does not include ginseng. It found that other dietary supplements did not improve cancer-related fatigue during or after treatment, and it rated the certainty of the evidence for fatigue treatments as low to moderate.
An important caveat: the Wisconsin trial used pure, encapsulated, root-powder American ginseng with documented ginsenoside content, not an arbitrary commercial product. The commercial ginseng marketplace is notorious for adulteration and underpotency (some studies have found commercial products with as little as 10% of the labeled ginsenoside content). The clinical results almost certainly do not generalize to the cheapest commercial preparations. For more on cancer care, see our Cancer page.
Chronic Fatigue Syndrome and Idiopathic Chronic Fatigue
The Kim 2013 trial enrolled 90 adults with idiopathic chronic fatigue (substantial fatigue for at least 6 months, no identifiable underlying cause, not meeting full myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) diagnostic criteria) and randomized them to 1 g/day or 2 g/day of a purpose-made 20% ethanol extract of Panax ginseng or placebo for 4 weeks. Fatigue was measured on a self-rating numeric scale and a visual analogue scale. Total numeric-scale scores fell with ginseng but did not differ significantly from placebo; mental-fatigue scores improved significantly on both doses, and only the 2 g dose significantly lowered the visual-analogue score (from 7.3 to 4.4, versus 7.1 to 5.8 on placebo). Mental fatigue measures improved more reliably than physical fatigue measures — a pattern that recurs across the ginseng cognitive trials.
For full myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the evidence is sparser and weaker. The dominant mechanism in myalgic encephalomyelitis/chronic fatigue syndrome is now thought to be mitochondrial dysfunction with secondary hypothalamic-pituitary-adrenal-axis dysregulation, autonomic dysfunction, and post-exertional malaise — a much more complex pathophysiology than ordinary fatigue. Small ginseng pilot studies in myalgic encephalomyelitis/chronic fatigue syndrome populations have shown trends toward improvement in vigor and reduction of post-exertional malaise frequency, but the trials have been underpowered. In diagnosed myalgic encephalomyelitis/chronic fatigue syndrome, crashing after even mild stimulation is the diagnostic hallmark of the condition, and the post-exertional malaise window falls 24-72 hours after activity — which is why cautious, small starting amounts are the approach usually described for any energy-supporting product in this condition.
For fibromyalgia, where central sensitization and sleep disruption are the dominant features rather than pure fatigue, ginseng has shown modest benefit in small trials, primarily on the fatigue subscore of the FIQ (Fibromyalgia Impact Questionnaire) rather than pain. Practitioners generally favour American ginseng (cooler) over Korean (warmer) in this population due to the high prevalence of comorbid anxiety and sleep disturbance.
Pooled Herbal Trials for Cancer-Related Fatigue
A 2026 systematic review and meta-analysis pooled 14 placebo-controlled randomized trials of herbal remedies for cancer-related fatigue, including Panax ginseng, guaraná (Paullinia cupana) and multi-herb Traditional Chinese Medicine formulas. Taken together, the herbal remedies gave a modest improvement in fatigue (standardized mean difference 0.31, 95% confidence interval 0.08 to 0.53), with substantial differences between trials. In the ginseng subgroup, the effect was not statistically significant. Most trials had a high or unclear risk of bias, and the authors rated the certainty of the evidence as very low; they concluded that current evidence does not firmly support herbal remedies as effective treatments for cancer-related fatigue and that well-designed multicentre trials are needed.
Mitochondrial Bioenergetics — The Mechanism Beneath the Effect
The molecular mechanism that ties together cancer-related fatigue, chronic fatigue, and the "wired-tired" pattern increasingly converges on mitochondrial bioenergetics. Cancer, chemotherapy, chronic viral infection, chronic stress, sleep deprivation, and aging all damage mitochondrial function: reduced adenosine triphosphate (ATP) production per molecule of glucose or fatty acid burned, increased reactive oxygen species generation, and reduced replicative capacity of the mitochondrial pool. Cells with damaged mitochondria experience "subjective fatigue" out of proportion to the work they are doing, because their per-cell energetic output is compromised.
Several ginsenosides act directly on mitochondria:
- Ginsenoside Rg1 — increases activity of mitochondrial respiratory complexes I and IV in skeletal muscle and brain tissue in preclinical models. The result is improved adenosine triphosphate synthesis efficiency per molecule of substrate oxidized.
- Ginsenoside Rb1 — reduces mitochondrial membrane lipid peroxidation and protects mitochondrial DNA from oxidative damage. Less mitochondrial DNA damage means longer functional lifespan of the mitochondrial pool.
- Ginsenoside Rg3 (the steaming-generated ginsenoside found primarily in Korean red ginseng) — in preclinical cancer models, increases mitochondrial biogenesis through PGC-1alpha pathway activation. PGC-1alpha is the master transcriptional regulator of mitochondrial proliferation in muscle and other tissues.
These mechanisms are mechanistically congruent with the clinical observation that ginseng helps most in conditions where mitochondrial damage is suspected to be a major driver of symptoms — cancer-related fatigue (chemo damages mitochondria), chronic fatigue syndromes, post-viral fatigue, and age-related sarcopenia. They are less directly congruent with conditions where the limiting factor is sleep, thyroid hormone, iron, or major depression — which is why ginseng is poor first-line therapy for those underlying issues.
For related mitochondrial-support compounds, see Vitamin B12 (one-carbon metabolism), Iron (oxygen delivery to mitochondria), Magnesium (adenosine triphosphate cofactor), and pyrroloquinoline quinone (PQQ) (preclinical mitochondrial biogenesis).
Hypothalamic-Pituitary-Adrenal-Axis Cortisol Normalization
The second well-documented mechanism is modulation of the hypothalamic-pituitary-adrenal (HPA) axis. In healthy humans, cortisol follows a robust diurnal rhythm — peak in the first hour after waking (cortisol awakening response, CAR), gradual decline through the day, low values in the evening, lowest values in the first half of the sleep period. Chronic stress, depression, chronic infection, post-traumatic stress disorder, burnout, and other "allostatic load" conditions tend to flatten this curve — lower morning peak, higher evening values — producing the clinical pattern of feeling exhausted in the morning but unable to wind down at night.
Ginsenoside supplementation in chronically stressed individuals (animal models and small human studies) tends to normalize the cortisol curve — raising the morning peak in flattened patterns, lowering the evening values in elevated patterns. This is the classical "adaptogen" action: it does not push cortisol uniformly up or uniformly down but pushes it toward the normal pattern from whichever direction it has drifted. This is the same mechanism documented for the other clinically validated adaptogens (Ashwagandha, Rhodiola, Eleuthero), and ginseng is the prototype on which the modern adaptogen concept was built.
For the broader picture of stress physiology, see our Stress Management page. For sister adaptogens with different stress-response profiles, see Ashwagandha (more sedative, better for anxiety-predominant patterns), Rhodiola Rosea (more energizing, better for depression-predominant patterns), and Holy Basil (gentler, good for sleep disruption).
Exercise Performance and Athletic Endurance
Ginseng has been studied as an ergogenic aid in athletic populations since the 1970s. The results have been genuinely mixed. The field's overall conclusion is that ginseng produces modest, real, but unimpressive benefits in performance metrics in trained athletes. A 2016 meta-analysis pooled 12 randomized placebo-controlled trials with 630 participants: in the 4 trials that measured fatigue, ginseng reduced it (standardized mean difference 0.34, 95% confidence interval 0.16 to 0.52), but in the 8 trials that measured physical performance it showed no gain (standardized mean difference -0.01). The authors judged the evidence insufficient for either use, because only a few small trials have been published. Across individual studies:
- Endurance trials (VO2max, time to exhaustion) have shown small benefits in some studies and null results in others. The benefit is more reliable in untrained subjects and less reliable in already-conditioned athletes.
- Recovery markers (post-exercise lactate clearance, perceived exertion at fixed intensity, soreness scores) favour ginseng in some small studies — for example, a 2005 study of seven healthy, untrained men found that 8 weeks of Panax ginseng extract lengthened treadmill time to exhaustion by 1.5 minutes and lowered a blood marker of oxidative damage (malondialdehyde) — but the pooled analysis above found no overall gain in physical performance.
- Strength performance (one-rep max, total volume) generally shows no benefit.
The pattern fits the mitochondrial mechanism: ginseng helps most when oxidative stress and recovery, rather than peak motor unit recruitment, are the limiting factor. Endurance athletes recovering from heavy training blocks may benefit more than power athletes peaking for competition. The amount commonly described for athletes is 200-400 mg/day of a 4%-7% standardized ginsenoside extract, divided between morning and early afternoon.
Practical Dosing and Forms
The amounts used in studies and in practice vary by indication and species:
- Cancer-related fatigue (American ginseng / Panax quinquefolius) — the Barton trials used 1,000-2,000 mg/day of root powder taken twice daily for 8 weeks (the phase 3 trial used 1,000 mg twice daily). The schedule described is 1,000 mg/day for the first week to assess tolerance, then 2,000 mg/day.
- Idiopathic chronic fatigue (Korean Panax ginseng) — the Kim 2013 trial used 1 g or 2 g/day of a 20% ethanol extract for 4 weeks; 1,000-2,000 mg/day of root powder or an equivalent extract is the amount commonly described. Korean red ginseng (the steamed form) is the most studied variant.
- General energy/adaptogen support — 200-400 mg/day of a standardized 4%-7% ginsenoside extract is the amount most commonly described. Equivalent root-powder dose is roughly 1-2 g/day.
- Athletic recovery — 200-400 mg/day standardized extract, described as taken during heavy training blocks rather than continuously.
Forms in descending order of evidence and quality:
- Korean red ginseng extract (KRG) — the most studied single form. Korean Panax ginseng steamed and dried, then extracted. Produces the highest concentration of Rg3 (the steaming-generated ginsenoside).
- Standardized ginsenoside extract — designed for consistent ginsenoside content. Standardized extracts are made from both Panax ginseng (Korean/Asian) and Panax quinquefolius (American).
- Pure root powder in capsules — whole-root powder. Cheapest, but most variable in ginsenoside content; some products carry independent third-party testing of their contents.
- Traditional decoctions (ginseng tea, ginseng soup) — centuries of traditional use. Ginsenoside content varies enormously with preparation; used for general tonic purposes; not the form tested in the clinical fatigue trials.
Ginseng is traditionally taken in the morning and early afternoon rather than the evening, because the mild stimulant effect of Rg1 is described as disrupting sleep when taken late. American ginseng is less likely to disrupt sleep than Korean red.
What Ginseng Does Not Do for Fatigue
Ginseng is not a panacea, despite the etymology of Panax. It does not address several common causes of fatigue:
- Iron deficiency anemia — ginseng has no effect on iron status. Iron deficiency shows on a ferritin test and complete blood count and is corrected with iron (see our Iron page).
- Hypothyroidism — ginseng does not replace levothyroxine. A thyroid-stimulating hormone (TSH) above 4-5 is the range usually investigated for an underactive thyroid; ginseng does not substitute for thyroid hormone.
- Vitamin B12 deficiency — particularly in vegetarians, vegans, and patients on metformin or proton pump inhibitor (PPI) medications. Deficiency shows on serum B12 and methylmalonic acid tests and is corrected with B12 taken under the tongue or by injection (see Vitamin B12 page).
- Sleep apnea — the single most common cause of treatment-resistant daytime fatigue in middle-aged adults. Loud snoring, witnessed apneas, gasping awakenings, morning headache, and unrefreshing sleep are the signs a sleep study is used to investigate. Ginseng will not address the underlying hypoxia.
- Major depression — fatigue is one of the nine DSM-5 depression criteria. Ginseng has no antidepressant effect; the underlying depression needs evaluation and treatment.
- Untreated sleep deprivation — ginseng does not substitute for sleep. Patients sleeping 5-6 hours per night will not energize sustainably on any adaptogen.
Ginseng works best when the underlying obvious causes of fatigue have been addressed and a residual "post-everything" fatigue remains, or when fatigue is attributable to a known driver (cancer, chronic infection, post-viral) that has been treated as well as it can be.
Cautions and Drug Interactions
- Warfarin interaction (most important) — ginseng can reduce the international normalized ratio (INR), the blood-clotting measure used to set warfarin doses. In a 2004 randomized placebo-controlled trial in 20 healthy volunteers (Yuan and colleagues, Annals of Internal Medicine), 2 weeks of American ginseng lowered the peak INR compared with placebo (difference -0.19) and also lowered blood warfarin levels; the authors concluded that American ginseng reduces warfarin's anticoagulant effect. The mechanism appears to be enzyme-induction of warfarin metabolism. A lower INR means less protection against clots.
- Insomnia and overstimulation — the most common adverse effect of Korean red ginseng. Morning-only use, a switch to American ginseng, or a lower amount are the changes traditionally described when it occurs.
- Headache and blood pressure — small reductions in blood pressure are common (typically clinically welcome); rare cases of paradoxical hypertensive headache occur, primarily with very high doses (>3 g/day).
- Hypoglycemia — ginseng has small blood-sugar-lowering effects. In people taking insulin or sulfonylurea drugs, this added effect can push blood sugar too low.
- Monoamine oxidase inhibitor (MAOI) interaction — rare but serious. Case reports of mania and serotonin-like syndromes in patients taking ginseng concurrently with monoamine oxidase inhibitors.
- Hormone-sensitive conditions — ginsenosides have weak estrogenic activity at high doses in preclinical models. This is the concern raised for people with estrogen-receptor-positive breast cancer, endometrial cancer, or active estrogen-sensitive uterine fibroids, in whom long-term use has not been studied (though the Barton breast cancer trial included primarily estrogen-receptor-positive patients without identified problems).
- Pregnancy and lactation — safety in pregnancy and breastfeeding has not been established. American ginseng is traditionally used for postpartum fatigue, but the evidence is limited.
- Children — there are no established safety data for children under 12; use in children is limited to specific traditional-medicine contexts.
Key Research Papers
- Barton DL et al. (2013). Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. Journal of the National Cancer Institute 105(16):1230-1238. — PubMed PMID: 23853057
- Barton DL et al. (2010). Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18(2):179-187. — PubMed PMID: 19415341
- Kim HG et al. (2013). Antifatigue effects of Panax ginseng C.A. Meyer: a randomised, double-blind, placebo-controlled trial. PLoS One 8(4):e61271. — PubMed PMID: 23613825
- Arring NM, Millstine D, Marks LA, Nail LM (2018). Ginseng as a treatment for fatigue: a systematic review. Journal of Alternative and Complementary Medicine 24(7):624-633. — PubMed PMID: 29624410
- Yennurajalingam S et al. (2015). High-dose Asian ginseng (Panax ginseng) for cancer-related fatigue: a preliminary report. Integrative Cancer Therapies 14(5):419-427. — PubMed PMID: 25873296
- Yuan CS et al. (2004). Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Annals of Internal Medicine 141(1):23-27. — PubMed PMID: 15238367
- Panossian A, Wikman G (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals 3(1):188-224. — PubMed PMID: 27713248
- Choi KT (2008). Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C.A. Meyer. Acta Pharmacologica Sinica 29(9):1109-1118. — PubMed PMID: 18718180
- Bach HV et al. (2016). Efficacy of ginseng supplements on fatigue and physical performance: a meta-analysis. Journal of Korean Medical Science 31(12):1879-1886. — PubMed PMID: 27822924
- Kim SH, Park KS, Chang MJ, Sung JH (2005). Effects of Panax ginseng extract on exercise-induced oxidative stress. Journal of Sports Medicine and Physical Fitness 45(2):178-182. — PubMed PMID: 16355078
- Bower JE, Lacchetti C, Alici Y, et al. (2024). Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. Journal of Clinical Oncology 42(20):2456-2487. — PubMed PMID: 38754041
- Matsas S, Medeiros Araujo de Matos U, Molina Llata C, Del Giglio A (2026). Efficacy of phytotherapy for cancer-related fatigue: a systematic review and meta-analysis of randomized controlled trials. Diseases 14(2):39. — PubMed PMID: 41745077